Lnmunopathogenesis of hepatitis C virus infection

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 31-38

  Ferrari, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEPATITIS C; HEPATITIS C ANTIBODIES; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR;

EID: 0033404541     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Doherty PC, Ahmed R. Immune response to viral infection. In: Nathanson N, editor. Viral Pathogenesis. Philadelphia: Lippincott-Raven: 1997. p. 143-161.
2. Parker DC. T cell-dependent B cell activation. Ann Rev Immunol 1993: 11:331-360.
3. Guidotti LG, Ando K, Hobbs MV, Ishikava T, Runkel L, Schreiber RD et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a non cytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994: 91: 3764-3768.
4. Guidotti LG, Ishikava T, Hobbs MV, Matzke B, Schreiber RD, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996: 4: 25-36.
5. Oldstone MD. Molecular anatomy of viral persistence. J Virol 1991: 65: 6381-6386.
6. Farci P, Alter HJ, Govindarajan S. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992: 258: 135-140.
7. Prince AM, Brotman B, Huima T, Pacual D, Jaffery M, Inchauspé G. Immunity in hepatitis C infection. J Infect Dis 1992: 165: 438143.
8. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994: 68: 1494-1500.
9. Farci P, Alter HJ, Wong DC. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994: 91: 7792-7796.
10. Van Doom LJ, Capriles I, Maertens G, DeLeys R, Murray K, Kos T et al. Sequence evolution of the hypervariable region in the putative envelope regionE2/NSl of hepatitis C virus is correlated with specific humoral immune responses. J Virol 1995: 69: 773-778.
11. McAllister J, Casino C, Davidson F, Power J, Lawlor E, Yap PL et al. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol 1998: 72: 4893-4905.
12. Manzin A, Solforosi L, Petrelli E, Macarri G , Tosone G , Piazza M et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 1998: 72: 6271-6276.
13. Farci P, Shimoda A, Wong D. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hyper variable region 1 of the envelope 2 perotein. Proc Natl Acad Sci USA 1996: 93: 15394-15399.
14. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996: 223: 409412
15. Rosa D, Campagnoli S, Moretto C. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996: 93: 1759-1763.
16. Mondelli MU. Is there a role for immune responses in the pathogenesis of hepatitis C? J Hepatol 1996: 25: 232-238.
17. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G et al. Evidence for immune selection of hepatitis C (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infection. Proc Natl Acad Sci USA 1992: 89: 34683472.
18. Kalo N, Sekiya H, Ootsuyama Y. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp 70) of hepatitis C virus. J Virol 1993: 67: 3923-3930.
19. Kumar U, Monjardino J, Thomas-HC. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 1994: 106: 1072-1075.
20. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995: 208: 653-661.
21. Shimizu YK, Purcell RH, Yoshikura H. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci USA 1993: 90: 6037-6041.
22. Kojima M, Osuga T, Tsuda F, Tanaka T, Okamoto-H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees.Virology 1994: 204: 665-672.
23. Lechner S, Rispeter K, Meisel H, Kraas W, Jung G, Roggendorf M et al. Antibodies directed to enveloe proteins of hepatitis C virus outside of hypervariable region 1. Virology 1998: 243: 313321.
24. Cerino A, Bissolati M, Cividini A, Nicosia A, Esumi M, Hayashi N et al. Antibody responses to the hepatitis C virus E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects. J Med Virol 1997: 51: 1-5.
25. Scarselli E, Cerino A, Esposito G, Silini E, Mondelli MU, Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J Virol 1995: 69: 4407-4412.
26. Cerino A, Mondelli MU. Identification of an immunodominant B cell epitope on the hepatitis C virus non structural region de-fined by human monoclonal antibodies. J Immunol 1991: 147: 2692-2696.
27. Cerino A, Boender P, La Monica M, Rosa C, Habets W, Mondelli MU. A human monoclonal antibody specific for the N-terminus of the hepatitis C virus nucleocapsid protein. J Immunol 1993: 151: 7005-7015.
28. Ferroni P, Mascolo G, Zaninetti M, Colzani D, Pregliasco F, Pirisi M et al. Identification of four epitopes in hepatitis C virus core protein. J Clin Microbiol 1993: 31: 1586-1591.
29. Simmonds P, Rose KA, Graham. Mapping of serotype-specific immunodominant epitopes in NS4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infection with HCV type 1, 2 and 3. J Clin Microbiol 1993: 31: 1493-1503.
30. Mondelli MU, Cerino A, Boender P. Significance of the immuno response to a major, conformational B cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody. J Virol 1994: 68: 4829-4836.
31. Pileri P, Uematsu Y, Campagnol! S, Galli G, Falugi F, Petracca R et al. Binding of hepatitis C virus to CD81. Science 1998: 282: 938-941.
32. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu13 molecules. J Immunol 1992: 149(9): 2841-2850.
33. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Ann Rev Immunol 1995: 13: 127-149.
34. Cooper NR, Moore MD, Nemerow GR. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Ann Rev Immunol 1988: 6: 85-113.
35. Germain RN. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 1994: 76: 287-299.
36. Yewdell JW. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 1992: 52: 1-123.
37. Monaco JJ. A molecular model of MHC class-I-restricted antigen processing. Immunol Today 1992: 13: 173-179.
38. Silver ML. Reconstitution by MHC-resricted peptides of HLAA2 heavy chain with /J2-microslobulin in vitro. Nature 1991: 350: 619-622.
39. Townsend A. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989: 340: 443-448.
40. Townsend A. Assembly of MHC class I molecules analyzed in vitro. Cell 1990: 62: 285-295.
41. Bjorkman PJ. Structure, function, and diversity of class I major histocompatibility complex molecules. Ann Rev Biochem 1990: 59: 253-258.
42. Saper MA. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 1991: 219: 277319. ;
43. Brown JH. The three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993: 364: 3339.
44. Rudensky AY. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991: 353: 622-627.
45. Hunt DF. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992: 256: 1817-1820.
46. Rudensky AY. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 1992: 359: 429-131.
47. Chicz RM. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992: 358: 764-768.
48. Konig R et al. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CDS. Nature 1992: 356: 796-798.
49. Cammarota G. Identification of a CD4 binding site of the b2 domain of HLA-DR molecules. Nature 1992: 356: 799-801.
50. Potter TA1. Substitution at residue 277 of H-2 class I molecules abrogates recognition by CDS-dependent, but not by CD8-independent, cytotoxic T lymphocytes. Nature 1989: 337: 73-75.
51. Salter RD. A binding site for T cell co-receptor CDS on the alpha-3 domain of HLA-A2. Nature 1990: 345: 416.
52. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC et al. Possible mechanism involving Tlymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995: 346: 1006-1007.
53. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C et al. Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the anti-viral cellmediated immune response. J Ciin Invest 1996: 98: 706-714.
54. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995: 13: 29-60.
55. Hoffmann RM, Diepolder HM, Zachoval R, Zwiebel FM, Jung MC, Scholz S et al. Mapping of immunodominant CD4+ T lymphocytes epitope of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995: 21: 632-636.
56. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997: 71: 6011-6019.
57. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997: 25: 449-158.
58. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994: 76: 241-251.
59. Sher A, Coffman RL. Regulation of immunity to parasites by T cells and T-cell derived cytokines. Ann Rev Immunol 1992: 10: 385-409.
60. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M et al. Long lasting memory T-cell responses following self-limited acute hepatitis B. J Clin Invest 1996: 98: 1185-1194.
61. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996: 2: 1104-1108.
62. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994: 19: 286-295.
63. Takaki A, Wiese M, Maertens G, Depla E, Liebetrau A, Manns M et al. A strong cellular, not humoral immune response distinguishes recovered from chronic patients 18 years after a single source outbreak of hepatitis C. Hepatology 1998: 28 (4): Abs n.630.
64. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996: 24: 790-795.
65. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997: 159: 1012-1018.
66. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ et ai. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993: 104: 580-587.
67. Battegay M, Fikes J, Di Biscieglie AM, Wentworth PA, Sette A, Celis E et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus encoded peptides binding to HLA-A2.1 molecule. J Virol 1995: 69: 24622470.
68. Cherny A, Me Hutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabbscheid B et al. Cytotoxic T lymphocyte response to hepatitis C virus derived peptides containing the HLA-A2.1 binding motif. J Clin Invest 1995: 95: 521-530.
69. Shirai M, Arichi T, Nishioka M, Nomura T, Icheda K, Kauanishi K et al. CTL Responses of HLA-A2.1-transgenic mice specific for hepatits C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995: 154: 2733-2742.
70. Kita H, Morijama T, Kaneko T, Harase I, Nomura M, Miura H et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993: 18: 1039-1043.
71. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991: 174: 1565-1570.
72. Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M et al. Compartmentalization of T-lymphocytes to the site of the disease: intrahepatic CD4+ T-cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993: 178: 17-26.
73. Lohr HF, Schlaak JF, Kollmannsperger S, Dienes HP, Meyer zum Buschenfelde KH, Gerken G. Liver-infiltrating and circulating CD4+ T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction and functional significance. Liver 1996: 16: 174182.
74. Koziel MJ, Dudley D, Wong J, Dienstag J, Houghton M, Ralston R et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992: 149: 3339-3344.
75. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL et al. HLA class I restricted cytotoxic T lymphocytes specific for hepatitis C virus: identification of multiple epitopes and characterization of patterns of cytokines release. J Clin Invest 1995: 96:2311-2315.
76. Wong DKH, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L et al. Liver derived CTL in Hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998: 160: 1479-1488.
77. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M et al. The role of hepatitis C virus specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997: 158: 14731481.
78. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JYN. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte acitivity and response to interferon alpha therapy in chronic hepatitis C. Hepatology 1998: 28: 225-230.
79. Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, Durazzo M et al. Different cytokine profiles of intrahepatic Tcells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997: 112: 193-199.
80. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Thl-associated cytokines. Hepatology 1996: 24: 759-765.
81. Carnma C, Almasio P, Craxi A. Interferon as treatment for hepatitis C. A meta-analysis. Dig Dis Sci 1996: 41: 1248-1255.
82. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effect of dose and duration. Hepatology 1996: 24: 778-789.
83. Simmonds P. Variability of hepatitis C virus. Hepatology 1995: 21: 570-581.
84. Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Scite A et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994: 180: 933-943.
85. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M et al. Natural variants of cytotoxic epitopes are T cell receptor antagonists for anti-viral cytotoxic T cells. Nature 1994: 369: 407-410.
86. Meier UC, Klenerman P, Griffin P, James W, Koppe B, Larder B et al. Cytotoxic T lymphocytes lysis inhibited by viable HIV mutants. Science 1995: 270: 1360-1362.
87. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995: 92: 2755-2759.
88. Tsai SL, Chen YM, Chen MH, Huang CY, Sheen IS, Yeh CT et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998:115:954-966.